Orthopedic Surgery Doctors in Orange, CA Accepting Medicare

89 Orthopedic Surgery doctors found. Showing 81 - 89

Laura Sonoda, M.D. Orthopaedic Surgery - Hand Surgery Medicare: Medicare Enrolled Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-456-7890

Dr. Brandon Albert Haghverdian, M.D. Orthopaedic Surgery - Foot and Ankle Surgery Medicare: Medicare Enrolled Practice Location: 280 S Main St Ste 200, Orange, CA 92868 Phone: 714-634-4567

David C Smith, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 280 S Main St, Ste 200, Orange, CA 92868 Phone: 714-634-4567    Fax: 714-634-4569

Dr. Tyler Johnston, M.D. Orthopaedic Surgery - Sports Medicine Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S Bldg 29a, Orange, CA 92868 Phone: 714-456-7801

Kevin Cyrus Parvaresh, M.D. Orthopaedic Surgery - Sports Medicine Medicare: Accepting Medicare Assignments Practice Location: 280 S Main St Ste 200, Orange, CA 92868 Phone: 714-634-4567

Jessica Cole Mcmichael, M.D. Orthopaedic Surgery - Pediatric Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1310 W Stewart Dr, Suite 508, Orange, CA 92868 Phone: 714-633-2111    Fax: 714-633-5615

Dr. Sohaib Hashmi, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-880-7812

Jay Patel, M.D. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 280 S Main St, Orange, CA 92868 Phone: 714-634-4567

Michael F Shepard, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 280 S Main St, Ste 200, Orange, CA 92868 Phone: 714-634-4567    Fax: 714-634-4569

News Archive

Svelte Medical completes 6 month follow up in initial Acrobat angioplasty system clinical trial

Svelte™ Medical Systems, Inc. is pleased to announce that it has completed 6 month follow up in its initial clinical trial with the Svelte Acrobat angioplasty system.

FDA grants Angion Biomedica's BB3 therapeutic Fast Track and Orphan Drug product designations

Angion Biomedica Corp., a biopharmaceutical company dedicated to the discovery and development of novel therapeutics that enhance quality of life, eradicate disease and save lives by modulating the body's protective, reparative and regenerative systems, announced today that its lead therapeutic BB3 was accepted into the Fast Track program of the U.S. Food and Drug Administration (FDA) and has also been designated an Orphan Drug product by FDA.

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.

TSRI professor receives $4.8 million grant to advance potential HIV vaccine research

Professor Michael Farzan, co-chair of the Department of Immunology and Microbiology on the Florida campus of The Scripps Research Institute has received $4.8 million in funding through a 2017 Avant-Garde Award for HIV/AIDS research from the National Institutes of Health's National Institute on Drug Abuse.

Read more Medical News

› Verified 9 days ago

• 1
• 2
• 3
• 4
• 5(current)